A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer
The combination of ionizing radiation and antiangiogenic agents seems to be a
counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a
reduction in oxygen concentration would be expected following a reduction in tumor
vasculature after antiangiogenic treatment.
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the safety and toxicity profile of sunitinib when used with concurrent radiation therapy
The purpose of this study is to determine the safety of the combination of the antiangiogenic, sunitinib, when combined with external beam radiotherapy.
Adam P Dicker, MD, PhD
Thomas Jefferson University
United States: Institutional Review Board
|Thomas Jefferson University||Philadelphia, Pennsylvania 19107-6541|